Radioisotope Market Size, Share, Growth and Forecast, 2025-2035

Therapy doses lift radioisotope value through 2035

The radioisotope market was valued at USD 6.15 billion in 2025 and is projected to increase from USD 6.67 billion in 2026 to USD 13.78 billion by 2035, registering a CAGR of 8.40% during 2025–2035. Demand rests on three forces, as radioligand cancer therapies need several high-value lutetium-177 doses per patient, SPECT and PET imaging grows steadily, and governments fund new molybdenum-99 supply after repeated reactor outages, including the 2024 shutdown of the HFR reactor in the Netherlands. North America held the largest regional share, 41.2% in 2025, led by U.S. adoption of lutetium-177 therapy and PSMA PET, while Asia Pacific is the fastest-growing region at 10.56% a year. The main commercial change is consolidation from target to patient. Curium signed an agreement in August 2026 to acquire Lantheus, after SHINE Technologies bought the Lantheus SPECT business in January 2026.

How do isotopes move from reactor to patient?

Supply runs through three steps, in which research reactors, power reactors, cyclotrons and accelerators irradiate targets; processors extract isotopes such as molybdenum-99 and lutetium-177; and radiopharmaceutical companies and nuclear pharmacies turn them into generators, tracers and unit doses delivered to hospitals each morning. Short half-lives mean most products cannot be stockpiled, so supply must match daily demand. Sealed sources such as cobalt-60 and iridium-192 follow a separate industrial route for sterilization, radiography and gauging.

The market includes molybdenum-99/technetium-99m generators and kits, cyclotron-made fluorine-18 and generator-made gallium-68, therapy isotopes including lutetium-177, iodine-131 and actinium-225, and industrial sealed sources, sold by radiopharmaceutical suppliers and isotope producers. It excludes stable isotopes and enriched targets sold before irradiation, scanners, cyclotrons and hot cells, nuclear power fuel and isotopes used only for weapons work.

Technetium-99m holds volume while lutetium-177 adds growth

Technetium-99m leads by isotope type while lutetium-177 grows fastest

Based on type of isotope, the market is categorized into technetium-99m, fluorine-18, lutetium-177, iodine-131 and other isotopes. Technetium-99m led with 31.6% of 2025 value, because hospitals elute it daily from molybdenum-99 generators for heart, bone, kidney and thyroid scans. Lutetium-177 grows fastest at 17.15% a year, as approved prostate and neuroendocrine cancer therapies need several cycles per patient and new indications keep adding treated patients.

Diagnostics lead applications while therapeutics grow fastest

Based on application, the market is categorized into diagnostics, therapeutics, industrial applications and research. Diagnostics led with 57.9% of 2025 value, because SPECT and PET scans run at high volume in every nuclear medicine department. Therapeutics grows fastest at 15.00% a year, as radioligand therapies turn the isotope into the active part of a cancer drug, which favors producers with qualified therapy-grade supply.

Hospitals lead end users while research institutions grow fastest

Based on end user, the market is categorized into hospitals and clinics, research institutions and industrial sectors. Hospitals and clinics led with 77.6% of 2025 value, buying generators, tracers and unit doses directly or through central radiopharmacies. Research institutions grow fastest at 9.14% a year, as alpha-emitter and new-target trials scale up and sponsors secure qualified actinium-225 and lutetium-177 for clinical studies.

Radioligand approvals and supply funding lift isotope demand

Radioligand therapy approvals widen the paying patient pool

Lutetium-177 compounds bind to tumor cells that carry a target receptor and deliver radiation from inside, and each of several cycles per patient needs a fresh, short-lived batch. In March 2025, the FDA cleared Pluvicto for PSMA-positive metastatic castration-resistant prostate cancer before chemotherapy, which Novartis said roughly triples the eligible population. Oncology centers in the U.S. and Europe drive this demand through 2035, as approved prostate and neuroendocrine cancer therapies win new indications that keep adding treated patients.

Imaging volumes keep a large technetium-99m and PET base

Technetium-99m is used in 80% to 85% of nuclear medicine procedures, according to the OECD Nuclear Energy Agency. The U.S. alone performs tens of thousands of technetium-99m procedures every day and has relied entirely on imports of molybdenum-99 for decades, according to the National Nuclear Security Administration. Aging populations add heart, bone and cancer scans each year, and every therapy patient needs a PSMA or somatostatin-receptor PET scan first, lifting fluorine-18 and gallium-68 demand alongside PET scanner access.

Download Free Sample

Governments fund molybdenum-99 supply after repeated outages

Six research reactors supply about 95% of the world's molybdenum-99, and 5 of them first operated between 1957 and 1974. When the HFR reactor in the Netherlands shut down in October 2024, shortages followed across several continents. In September 2025, the NNSA selected SHINE Technologies to finish its plant in Janesville, Wisconsin and since January 2026, Medicare has paid a per-dose add-on for technetium-99m made from domestic, non-HEU molybdenum-99. Beyond the U.S., Argentina, Brazil, China and Japan are building capacity too, which should reduce the risk of the shortages that followed the HFR shutdown.

Accelerators and power reactors open new production routes

New production routes now reduce dependence on old research reactors. NorthStar makes actinium-225 by electron accelerator in Beloit, Wisconsin, SHINE makes non-carrier-added lutetium-177 at its Cassiopeia plant, and Bruce Power in Canada has doubled its lutetium-177 output capacity since 2022, according to the NEA. More qualified sources let drug developers sign multiyear contracts with two suppliers, which supports research institutions and lowers supply risk for therapy launches.

Producer takeovers and alpha emitters reshape isotope supply

Isotope producers shift into finished drugs

Producers that once sold bulk isotope now want the margin on the final dose. Curium signed a definitive agreement on 3 August 2026 to acquire Lantheus, according to a filing with the U.S. Securities and Exchange Commission, with closing expected in the first half of 2027. SHINE completed its purchase of the Lantheus SPECT business on 2 January 2026, taking over the TechneLite generator, and BWXT agreed to sell its medical isotope unit to Nordic Capital. As a result, fewer, larger groups will control more of the chain.

Imaging and therapy are planned and sold as pairs

A PET scan selects the patient and a therapy isotope treats them. Fluorine-18 or gallium-68 tracers confirm that a tumor carries the target, and lutetium-177 or actinium-225 agents follow. Hospitals now add shielded therapy rooms next to PET suites, and Novartis opened its third U.S. radioligand therapy plant, in Carlsbad, California, in November 2025, with sites planned in Florida and Texas. Regional medical cyclotron sites put more value within a few hours of the patient.

Download Free Sample

Alpha emitters and second-source therapy isotopes open an opportunity

Drug developers are moving toward alpha emitters such as actinium-225, which deposit more energy over a shorter path. NorthStar reported routine commercial-scale actinium-225 production in January 2026, and the FDA accepted its drug master file in April 2026. SHINE received EU authorization for its Ilumira lutetium-177 precursor in May 2026, and Eckert & Ziegler is expanding actinium output in Germany and the Czech Republic. That matters because trial sponsors want 2 independent sources before they file.

Domestic molybdenum-99 and underserved therapy networks offer an opportunity

Japan aims to cover about 30% of its molybdenum-99 demand from domestic production by the end of fiscal 2027. Argentina's RA-10 reactor is about 96% complete and is designed to meet about 20% of global demand, and Brazil's RMB reactor targets self-sufficiency from 2031. Gulf states, India and parts of Latin America are opening cancer centers without local dose production, where suppliers that partner early gain a position.

Aging reactors and manufacturing scrutiny cap supply growth

Aging research reactors leave no buffer against outages

Molybdenum-99 has a 66-hour half-life and loses about 1% of its activity every hour, so no stockpile can bridge an outage. Most reactors that irradiate it are more than 50 years old, and the European Commission's SAMIRA action plan says research reactors will need major refurbishment or replacement by 2030. PALLAS in Petten started construction in September 2025 but is not due to run commercially until 2032. Hospitals face cancelled scans; accelerator routes and new reactors are the mitigation.

Manufacturing quality now decides therapy approvals

ITM received an FDA complete response letter in August 2026 for its lutetium-177 edotreotide candidate in neuroendocrine tumors. The agency cited chemistry, manufacturing and controls items and findings at a third-party site, and raised no clinical concerns. The delay holds back a second lutetium-177 option for patients and revenue for its supplier. Developers respond by building their own dose plants, qualifying backup suppliers and investing in good manufacturing practice before filing.

High entry costs and fragile logistics deter new suppliers

Every step needs shielded hot cells, licensed staff and special transport, and each change of supplier triggers fresh drug and radiation-safety qualification. Some airlines refuse radioactive cargo, forcing longer routes for products that decay by the hour. Diagnostic reimbursement has often lagged the full cost of supply, leaving producers little incentive to fund spare capacity. Full-cost-recovery pricing and payments such as the U.S. domestic molybdenum-99 add-on help close that gap.

Specialist staff and therapy room shortages limit treated patients

Radioligand therapy needs nuclear medicine physicians, physicists, radiopharmacists and shielded rooms that many hospitals lack, and patients outside large cities often have no center within reach. Hospitals hesitate to build therapy rooms before payers commit, and payers wait for local outcome data. The result caps treated patients even where isotope supply exists. Training programs, regional dose manufacturing and reimbursement support from drug makers are the main ways to raise that ceiling.

North America pays most while Asia Pacific builds fastest

North America grows on therapy adoption and domestic supply policy

North America held 41.2% of 2025 value and grows at 7.96% a year. The U.S. leads adoption of lutetium-177 therapy and PSMA PET, and federal policy now rewards domestic molybdenum-99 through the NNSA award to SHINE and the Medicare add-on. Canada remains a key supplier through Nordion, BWXT Medical and the CANDU reactors that produce about 50% of the world's cobalt-60. Cardinal Health's nuclear pharmacies deliver unit doses across the U.S.

Europe hosts dense imaging networks and the main molybdenum-99 reactors

Europe held 27.6% of 2025 value and grows at 6.86% a year. Germany, France and the United Kingdom have dense nuclear medicine networks, while Belgium, the Netherlands, Czechia and Poland host reactors that irradiate molybdenum-99 for export. Uneven reimbursement keeps therapy uptake in Southern and Eastern Europe behind the west. In March 2026, the European Commission published a feasibility and basic design study for the European Radioisotope Valley Initiative to strengthen regional supply.

Download Free Sample

Asia Pacific grows fastest on national isotope plans

Asia Pacific held 21.9% of 2025 value and is the fastest-growing region at 10.56% a year. China has a medical isotope plan running to 2035, and CNNC began commercial lutetium-177 production at Qinshan in 2025. Japan imports nearly all its molybdenum-99 but aims for about 30% domestic supply by fiscal 2027, while India, South Korea and Australia combine domestic reactors, including Australia's OPAL, with growing PET networks that support therapy selection.

Latin America and Middle East & Africa add new reactors and cancer centers

Latin America held 4.9% of 2025 value and grows at 8.76% a year. Argentina's RA-10 and Brazil's RMB aim to cut import dependence, and Brazil signed its RMB memorandum with INVAP in September 2025. The Middle East & Africa held 4.4% and grows at 9.26% a year. South Africa's SAFARI-1 is one of the six main molybdenum-99 reactors, and Gulf states are adding cyclotrons and therapy centers.

Download Free Sample

A Lantheus takeover and a new Novartis plant mark 2025–2026

Accelerators and alpha emitters define isotope technology

• Accelerator production uses electron accelerators and cyclotrons to make actinium-225, molybdenum-99 and PET isotopes without highly enriched uranium targets.
• Non-carrier-added lutetium-177 of higher purity from dedicated plants and power reactors supports therapy scale-up and dual sourcing.
• Alpha emitters such as actinium-225 deposit more energy over a shorter path than beta emitters, and supply is now moving from trial to commercial scale.
• Theranostic pairing of matched PET tracers and therapy agents lets hospitals select patients and plan doses with one target.
• Industrial alternatives such as electron-beam and X-ray sterilization and digital radiography compete with cobalt-60 and iridium-192 sealed sources.

Producers, drug makers and nuclear pharmacies compete

Competition runs across three layers, starting with isotope producers that irradiate and process targets. Curium supplies molybdenum-99, iodine-131 and lutetium-177, NTP Radioisotopes processes molybdenum-99 from SAFARI-1, Eckert & Ziegler supplies isotopes and sealed sources and Nordion supplies cobalt-60, while SHINE Technologies and NorthStar Medical Radioisotopes lead non-reactor routes. In the second layer, radiopharmaceutical companies turn isotopes into drugs, as Novartis owns Pluvicto and Lutathera, Bayer sells radium-223, and Lantheus, GE HealthCare and Bracco Imaging lead in PET and SPECT diagnostics. In the third, Cardinal Health runs one of the largest U.S. nuclear pharmacy networks. Entry barriers are high because licensed facilities, reactor access and drug master files take years to secure. Credence Research estimates the 10 largest suppliers hold well over half of global value, while fluorine-18 stays spread across hundreds of local cyclotron sites.

Producers, drug makers and distributors in the radioisotope supply chain

Isotope value is moving from scan volume to therapy doses

Credence Research's view is that radioisotope value is shifting from the volume of diagnostic scans to the number of therapy doses. A technetium-99m dose is cheap, while each lutetium-177 or actinium-225 patient needs several high-value doses plus PET scans. The largest new revenue lies in therapy isotopes, alpha emitters and paired PET tracers. Suppliers with qualified, non-reactor or dual-sourced production are best positioned. The main risk is a reactor outage or a manufacturing finding that delays approvals. Investors should watch the Curium-Lantheus closing and new reactor start dates.

How Credence Research built the radioisotope estimates

The report uses 2025 as the base year and forecasts to 2035, with CAGR calculated over 2025–2035. Market values come from Credence Research's market model, built from imaging procedure counts, treated therapy patients and cycles per patient, and sealed-source demand, and checked against reactor and cyclotron capacity reported by the NEA and national programs; segment and regional splits are Credence Research estimates. Supporting evidence comes from agency reports, regulatory notices and company filings.

Therapy isotopes and domestic molybdenum-99 set the pace

Through 2035, radioisotope value will tilt from diagnostic volume toward therapy doses. Lutetium-177 and actinium-225 demand will rise with new indications, while technetium-99m remains the volume base. Accelerator plants, power-reactor routes and new research reactors in Argentina, Brazil and Europe will reduce dependence on aging reactors, though PALLAS is not due until 2032. Asia Pacific will gain share as China and Japan build domestic supply. The pace will depend on manufacturing quality, specialist staff training and payer support for therapy rooms and dosimetry.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.